Compression Therapy Market to Reach USD 5.76 Bn by 2031 Driven by Rising Venous Disorders and Advanced Compression Technologies, Says Mordor Intelligence

Mordor Intelligence projects the global compression therapy market will grow from $4.52 billion in 2026 to $5.76 billion by 2031, a 4.96% CAGR. Demand is being supported by rising venous and lymphatic disorders, aging populations, and greater adoption of home-based care, while smart textiles, pressure monitoring, and dynamic compression pumps provide product-growth opportunities. Static compression and garments currently lead their categories, but dynamic systems, compression pumps, and home healthcare are expected to grow faster.

Analysis

This is not a standalone earnings catalyst: a sub-5% category growth estimate is insufficient to change valuation without evidence of share gains, reimbursement improvement, or materially higher pump utilization. TCMD has the clearest read-through because home pneumatic compression is closer to its core channel, but the relevant KPI is not market size; it is patient starts, referral conversion, payer-authorization duration, and revenue per patient. SOLV's exposure is more likely to be diluted by its broader wound-care and medical-solutions portfolio, making any compression-tailwind immaterial to consolidated estimates.

The higher-margin opportunity lies in home-based dynamic systems and digitally supported adherence, but this also raises execution risk. Payers may treat connected functionality as feature inflation unless it demonstrably reduces ulcer recurrence, admissions, or clinician time; without reimbursement, adoption shifts toward lower-priced garment alternatives. Over 6-18 months, scale distribution and payer contracting should matter more than sensor technology, favoring incumbents with clinical-sales infrastructure while pressuring smaller garment specialists and private-label suppliers.

Consensus may over-credit consumer wellness and smart-textile narratives. Sports-recovery demand is fragmented, promotional, and unlikely to support medical-device multiples; the investable signal would instead be a sustained increase in covered home-care utilization. Near-term upside for TCMD is underwritten only if upcoming results show faster patient-start growth and stable gross margin despite payer mix, while a deterioration in authorization timing or reimbursement policy would quickly negate the thesis.

Key Decisions for Investors

• Maintain TCMD on a 1-3 month earnings watch rather than initiate on this report. Go long only if management reports accelerating patient starts and stable/improving gross margin alongside unchanged reimbursement assumptions; failure of either metric falsifies the home-pump share-gain thesis.
• Do not use SOLV as a primary compression-therapy expression. Any category upside is likely too small versus portfolio-level drivers; retain SOLV exposure only where supported by its broader separation, deleveraging, and operating-margin thesis.
• Conditional relative-value trade: long TCMD versus short a diversified medtech proxy such as IHI only after verified reimbursement or utilization evidence. Target a 10-15% relative move over 6-12 months, with exit if payer authorization cycles lengthen or TCMD guides patient growth below prior trajectory.
• Monitor CMS/commercial payer coverage updates and TCMD disclosures on referral conversion, days-to-authorization, and revenue per patient. These are the highest-sensitivity catalysts over the next two quarters; generic market-growth reports should not drive position sizing.